1. Home
  2. SAFE vs ABCL Comparison

SAFE vs ABCL Comparison

Compare SAFE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$13.79

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$3.52

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFE
ABCL
Founded
2016
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SAFE
ABCL
Price
$13.79
$3.52
Analyst Decision
Buy
Buy
Analyst Count
9
5
Target Price
$19.56
$7.75
AVG Volume (30 Days)
416.2K
3.8M
Earning Date
02-04-2026
11-06-2025
Dividend Yield
5.02%
N/A
EPS Growth
N/A
N/A
EPS
1.57
N/A
Revenue
$398,968,000.00
$35,325,000.00
Revenue This Year
$0.84
$25.45
Revenue Next Year
$3.56
$10.07
P/E Ratio
$8.98
N/A
Revenue Growth
2.96
7.17
52 Week Low
$12.76
$1.89
52 Week High
$21.24
$6.52

Technical Indicators

Market Signals
Indicator
SAFE
ABCL
Relative Strength Index (RSI) 47.22 37.44
Support Level $13.24 $3.51
Resistance Level $13.87 $3.86
Average True Range (ATR) 0.40 0.18
MACD 0.10 0.07
Stochastic Oscillator 39.38 21.59

Price Performance

Historical Comparison
SAFE
ABCL

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: